FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1967926744> ?p ?o ?g. }

• W1967926744 endingPage "S73" @default.
• W1967926744 startingPage "S66" @default.
• W1967926744 abstract "Australian Aborigines in remote areas are experiencing an epidemic of renal and cardiovascular disease. In November 1995, we introduced a renal and cardiovascular treatment program into the Tiwi community, which has a three- to fivefold increase in death rates and a recent annual incidence of treated end-stage renal disease (ESRD) of 2760 per million. Our previous study described an estimated 50% reduction in renal failure and all-cause natural deaths in the treatment group through December 31, 1998. We now describe a reduction in these events through mid 2000.People eligible for treatment were those with confirmed hypertension, diabetics with microalbuminuria or overt albuminuria, and people with overt albuminuria, regardless of blood pressure and diabetes. Treatment centered around the use of perindopril (Coversyl, Servier), with additional agents as needed to reach defined blood pressure goals, attempts at control of glucose and lipid levels, and health education. Two hundred and sixty-seven people, or 30% of the adult population, have been enrolled, with mean follow up of 3.39 years. Rates of terminal endpoints were compared on an intention-to-treat basis with those of 327 historical controls matched for baseline disease severity, who were followed for a mean of 3.18 years in the pre-treatment program era, against a background of no treatment or inconsistent changing treatment.Terminal events occurred in 38 controls and 23 people in the treatment group. The estimated rate of natural deaths in the treatment group was 50% that of the controls, (P=0.012); the rate of renal deaths was 47% (P=0.038) and the rate of non-renal deaths was 54% that of controls (P=0.085). Survival benefit in the treatment group was observed at all levels of overt albuminuria, in non-diabetics and diabetics, in normotensive as well as hypertensive people, and in people who had been taking angiotensin converting enzyme-inhibitors (ACEi) in the pre-program era, as well as those who had not. Benefit was absent among the low death rates of people without overt albuminuria, and questionable among people with glomerular filtration rates (GFRs) <60 mL/min. The number of people needed to treat (NNT) to avoid one terminal event of natural causes was calculated at only 11.6.Falling rates of deaths and renal failure in the whole community support marked benefit of the program. Millions of dollars have been saved, based on avoidance of dialysis alone, but the reduction in premature death is the greater benefit. Chronic disease programs like this are enormously effective, and should be introduced into to all high-risk communities as a matter of urgency." @default.
• W1967926744 created "2016-06-24" @default.
• W1967926744 creator A5007275882 @default.
• W1967926744 creator A5035513602 @default.
• W1967926744 creator A5054358636 @default.
• W1967926744 creator A5083835115 @default.
• W1967926744 date "2003-02-01" @default.
• W1967926744 modified "2023-09-26" @default.
• W1967926744 title "Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community" @default.
• W1967926744 cites W142522710 @default.
• W1967926744 cites W1550111394 @default.
• W1967926744 cites W180946569 @default.
• W1967926744 cites W197185462 @default.
• W1967926744 cites W2015008239 @default.
• W1967926744 cites W2034927740 @default.
• W1967926744 cites W2086179413 @default.
• W1967926744 cites W2100124500 @default.
• W1967926744 cites W2104530858 @default.
• W1967926744 cites W2125779260 @default.
• W1967926744 cites W2128505617 @default.
• W1967926744 cites W2128958662 @default.
• W1967926744 cites W2257184644 @default.
• W1967926744 cites W3022929210 @default.
• W1967926744 cites W4328001511 @default.
• W1967926744 doi "https://doi.org/10.1046/j.1523-1755.63.s83.14.x" @default.
• W1967926744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12864878" @default.
• W1967926744 hasPublicationYear "2003" @default.
• W1967926744 type Work @default.
• W1967926744 sameAs 1967926744 @default.
• W1967926744 citedByCount "63" @default.
• W1967926744 countsByYear W19679267442012 @default.
• W1967926744 countsByYear W19679267442013 @default.
• W1967926744 countsByYear W19679267442014 @default.
• W1967926744 countsByYear W19679267442015 @default.
• W1967926744 countsByYear W19679267442016 @default.
• W1967926744 countsByYear W19679267442017 @default.
• W1967926744 countsByYear W19679267442018 @default.
• W1967926744 countsByYear W19679267442019 @default.
• W1967926744 countsByYear W19679267442020 @default.
• W1967926744 countsByYear W19679267442021 @default.
• W1967926744 countsByYear W19679267442022 @default.
• W1967926744 crossrefType "journal-article" @default.
• W1967926744 hasAuthorship W1967926744A5007275882 @default.
• W1967926744 hasAuthorship W1967926744A5035513602 @default.
• W1967926744 hasAuthorship W1967926744A5054358636 @default.
• W1967926744 hasAuthorship W1967926744A5083835115 @default.
• W1967926744 hasBestOaLocation W19679267441 @default.
• W1967926744 hasConcept C120665830 @default.
• W1967926744 hasConcept C121332964 @default.
• W1967926744 hasConcept C126322002 @default.
• W1967926744 hasConcept C134018914 @default.
• W1967926744 hasConcept C163276114 @default.
• W1967926744 hasConcept C177713679 @default.
• W1967926744 hasConcept C2776174234 @default.
• W1967926744 hasConcept C2778653478 @default.
• W1967926744 hasConcept C2779134260 @default.
• W1967926744 hasConcept C2779200603 @default.
• W1967926744 hasConcept C2781203188 @default.
• W1967926744 hasConcept C2908647359 @default.
• W1967926744 hasConcept C3019040382 @default.
• W1967926744 hasConcept C555293320 @default.
• W1967926744 hasConcept C61511704 @default.
• W1967926744 hasConcept C71924100 @default.
• W1967926744 hasConcept C84393581 @default.
• W1967926744 hasConcept C99454951 @default.
• W1967926744 hasConceptScore W1967926744C120665830 @default.
• W1967926744 hasConceptScore W1967926744C121332964 @default.
• W1967926744 hasConceptScore W1967926744C126322002 @default.
• W1967926744 hasConceptScore W1967926744C134018914 @default.
• W1967926744 hasConceptScore W1967926744C163276114 @default.
• W1967926744 hasConceptScore W1967926744C177713679 @default.
• W1967926744 hasConceptScore W1967926744C2776174234 @default.
• W1967926744 hasConceptScore W1967926744C2778653478 @default.
• W1967926744 hasConceptScore W1967926744C2779134260 @default.
• W1967926744 hasConceptScore W1967926744C2779200603 @default.
• W1967926744 hasConceptScore W1967926744C2781203188 @default.
• W1967926744 hasConceptScore W1967926744C2908647359 @default.
• W1967926744 hasConceptScore W1967926744C3019040382 @default.
• W1967926744 hasConceptScore W1967926744C555293320 @default.
• W1967926744 hasConceptScore W1967926744C61511704 @default.
• W1967926744 hasConceptScore W1967926744C71924100 @default.
• W1967926744 hasConceptScore W1967926744C84393581 @default.
• W1967926744 hasConceptScore W1967926744C99454951 @default.
• W1967926744 hasLocation W19679267441 @default.
• W1967926744 hasLocation W19679267442 @default.
• W1967926744 hasOpenAccess W1967926744 @default.
• W1967926744 hasPrimaryLocation W19679267441 @default.
• W1967926744 hasRelatedWork W1551788968 @default.
• W1967926744 hasRelatedWork W1763662287 @default.
• W1967926744 hasRelatedWork W2021663164 @default.
• W1967926744 hasRelatedWork W2072953734 @default.
• W1967926744 hasRelatedWork W2073426540 @default.
• W1967926744 hasRelatedWork W2151509478 @default.
• W1967926744 hasRelatedWork W2159455609 @default.
• W1967926744 hasRelatedWork W2434391732 @default.
• W1967926744 hasRelatedWork W4238073776 @default.
• W1967926744 hasRelatedWork W4297198580 @default.
• W1967926744 hasVolume "63" @default.

• next